Lymphoid Malignancies and Precursors Tissue Collection Protocol for Research Studies
Led by National Cancer Institute (NCI) · Updated on 2026-10-26
1295
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are collecting various tissue samples to study lymphoid cancers and their precursors, including multiple myeloma, different lymphomas, and adult leukemialymphoma. The study aims to improve understanding of cancer biology to help develop new diagnostic methods and treatments. This observational study involves participants with lymphoid malignancies as well as those undergoing surgery without known lymphoid disease.
Participants may provide blood, urine, bone marrow, tumor tissue, and skin tissue samples for research. Blood samples are collected at initial testing and at various treatment points. Tumor and skin biopsies may be obtained either from routine care procedures or surgical operations. The study does not involve providing any treatment.
Participants will undergo physical exams and medical history reviews for screening. Samples will be analyzed using cellular, molecular, genetic, and genomic techniques to support research into new therapies and diagnostic models. The study tracks sample collection continuously and may include additional assessments based on participant status. Participation involves consenting to sample collection and data use, with no treatment provided as part of the study.
CONDITIONS
Brief Title
Tissue Collection for Studies of Lymph Cancer
Research Team
N
NCIMO Referral Office
C
Christopher J Melani, M.D.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Patients with a confirmed lymphoid malignancy or precursor disease including multiple myeloma, B-cell and T-cell lymphomas
Pathological diagnosis confirmed by the Laboratory of Pathology, NCI
Adults aged 18 years or older
Ability and willingness to provide informed consent or have a legally authorized representative consent on their behalf
Patients without known lymphoid malignancy scheduled for surgery where tissue or blood may be collected for research
Ability and willingness to provide informed consent for patients without known lymphoid malignancy
You will not qualify if you...
Pregnant individuals
Active symptomatic major organ disorders increasing biopsy risk, such as ischemic heart disease, recent heart attack, congestive heart failure, or lung dysfunction
Active medical or psychological illnesses increasing risk or preventing informed consent
For patients without known lymphoid malignancy: presence of other active malignancies except for certain treated skin cancers or in situ carcinomas
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility through a physical exam and review of medical history.
Sample Collection
Duration - Ongoing
Participants provide blood, urine, bone marrow, tumor tissue, and skin tissue samples during initial testing and at various treatment points or surgeries. No treatment is provided as part of the study.
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Evaluating 18F-Fluciclovine PETCT Imaging for Multiple Myeloma Detection and Monitoring
Evaluating 68Ga-BCMA PETCT Imaging for Detecting BCMA in Multiple Myeloma Patients in a Multicenter Study
Italian National Registry to Monitor Diagnosis and Treatment of Multiple Myeloma
A Physician and Patient-Powered Cohort Study
Evaluating BCMA-Targeted Prime CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma and Plasma Cell Disease
Phase 1 Study of Subcutaneous TQB2934 Injection for Treating Malignant Plasma Cell Tumors Including Multiple Myeloma
Study of Allogeneic CD19 and BCMA CAR-T Cell Therapy for Adults with Relapsed or Refractory B-cell or Plasma Cell Tumors
Early Phase 1 Trial to Assess Safety and Effectiveness of RN1101 Treatment
Study Evaluating Safety and Effects of MK-1045 Immunotherapy in People with Follicular and Diffuse Large B-Cell Non-Hodgkin Lymphoma
Phase I Open-Label Study of SHR-5421 Injection Evaluating Safety and Preliminary Effects in Patients With Multiple Myeloma
Phase I Study of SHR-9539 Injection to Evaluate Safety and Effectiveness in Adults With Multiple Myeloma
Phase 1 Study of TQB2029 Injection to Test Safety and Effects in Adults With Multiple Myeloma
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma.